 |
 Video: What is a Stock Split?
|
|
|
| GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. According to our CBIO split history records, Crescent Biopharma has had 4 splits. | |
|
Crescent Biopharma (CBIO) has 4 splits in our CBIO split history database. The first split for CBIO took place on August 21, 2015. This was a 1 for 7 reverse split, meaning for each 7 shares of CBIO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split. CBIO's second split took place on February 13, 2017. This was a 1 for 15 reverse split, meaning for each 15 shares of CBIO owned pre-split, the shareholder now owned 1 share. For example, a 142.857142857143 share position pre-split, became a 9.52380952380952 share position following the split. CBIO's third split took place on September 21, 2022. CBIO's 4th split took place on June 16, 2025. This was a 1 for 100 reverse split, meaning for each 100 shares of CBIO owned pre-split, the shareholder now owned 1 share. For example, a 9.52380952380952 share position pre-split, became a 0.0952380952380952 share position following the split.
When a company such as Crescent Biopharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CBIO split history from start to finish, an original position size of 1000 shares would have turned into 0.0952380952380952 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Crescent Biopharma shares, starting with a $10,000 purchase of CBIO, presented on a split-history-adjusted basis factoring in the complete CBIO split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
07/21/2015 |
|
| End date: |
07/18/2025 |
|
| Start price/share: |
$78,960.00 |
|
| End price/share: |
$13.34 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.98% |
|
| Average Annual Total Return: |
-58.05% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1.69 |
|
| Years: |
10.00 |
|
|
|
| Date |
Ratio |
| 08/21/2015 | 1 for 7 | | 02/13/2017 | 1 for 15 | | 09/21/2022 | 1 for 1 | | 06/16/2025 | 1 for 100 |
|
|
Free CBIO Email Alerts:
